Response to Comments: MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma

This document (Policy A59394) is an administrative response to comments on the MolDX Local Coverage Determination DL39345 for molecular assays in cutaneous melanoma and records the comment, notice, and effective dates. It does not include clinical coverage criteria, indications, limitations, documentation requirements for claims, or frequency limits.

"Administrative notice: comment period for MolDX LCD DL39345 (Molecular Assays for the Diagnosis of Cutaneous Melanoma) ran 06/23/2022–08/06/2022; notice period begins 06/22/2023 and policy becomes ..."

Sign up to see full coverage criteria, indications, and limitations.